Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Pfizer – Roivant tie-up generates positive mid-stage data for lead asset [Seeking Alpha]Seeking Alpha
- Priovant's Brepocitinib Shows Skin Disease Improvement in Phase 2 Study; Pulmovant Completes Lung Disease Trial Enrollment [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences GAAP EPS of -$0.38 misses by $0.07, revenue of $1.99M misses by $4.15M [Seeking Alpha]Seeking Alpha
- Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)GlobeNewswire
- Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)GlobeNewswire
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 2/6/26 - Form 10-Q
- 2/6/26 - Form 8-K
- 2/5/26 - Form SCHEDULE
- ROIV's page on the SEC website